Publikationen in Zusammenarbeit mit Forschern von Universidad Autónoma de Madrid (19)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

2023

  1. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma

    Journal of Thrombosis and Thrombolysis, Vol. 55, Núm. 3, pp. 464-473

  2. NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells

    Frontiers in Immunology, Vol. 14

2022

  1. Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits

    Leukemia and Lymphoma

  2. Overcoming tumor resistance mechanisms in CAR-NK cell therapy

    Frontiers in Immunology, Vol. 13

2021

  1. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 5, pp. 328-337.e1

2020

  1. Tyk2 variants in b-acute lymphoblastic leukaemia

    Genes, Vol. 11, Núm. 12, pp. 1-16

2019

  1. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

    Haematologica, Vol. 104, Núm. 2, pp. 288-296

  2. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. How do we manufacture clinical-grade interleukin-15–stimulated natural killer cell products for cancer treatment?

    Transfusion, Vol. 58, Núm. 6, pp. 1340-1347

  2. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase

    PLoS ONE, Vol. 12, Núm. 7

2014

  1. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation

    Leukemia, Vol. 28, Núm. 6, pp. 1334-1340

2012

  1. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients

    BMC Gastroenterology, Vol. 12

2011

  1. Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients

    BMC Gastroenterology, Vol. 11

2010

  1. Simplifying the detection of MUTYH mutations by high resolution melting analysis

    BMC Cancer, Vol. 10

2009

  1. Long-term follow-up of donor chimerism and tolerance after human liver transplantation

    Liver Transplantation, Vol. 15, Núm. 6, pp. 581-591